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Previous work has also revealed that the activation of AT 1 R results in arachidonic acid (AA) release from membrane phospholipids by phospholipases A 2 (PLA 2 ) (54) . AA is then metabolized to prostaglandin E 2 (PGE 2 ) by cyclooxygenase-1 (COX-1) or cyclooxygenase-2 (COX-2). Accumulating evidence suggests that COX-derived PGE 2 plays important roles in the regulation of cardiovascular dysfunctions, including ANG II-induced hypertension (4, 6, 21, 39, 40, 45, 56) . The PGE 2 receptor subtype 1 (EP 1 R) is expressed in the SFO, and studies using genetically modified mice have shown that it plays an important role in signaling the onset of slow-pressor ANG-II hypertension (6, 21) . As a member of the G proteincoupled receptor family (17, 25) , EP 1 R is involved not only in ANG II-elicited ROS production in the SFO (6) but also in the regulation of Ca 2ϩ influx through Ca 2ϩ channels in neurons and neuroendocrine cells (4, 24, 25, 34) . To better understand the complex mechanisms underlying hypertension, it is essential to determine if and how PGE 2 , EP 1 R, ROS, and Ca 2ϩ are functionally linked to serve as key intermediate molecules in ANG II-mediated signaling in SFO neurons.
In this study, we sought to uncover the roles of key prostanoid-linked signals, including PLA 2 , COX-1, COX-2, and EP 1 R, in ANG II-elicited ROS production and voltage-gated Ca 2ϩ influx. Using electron microscopic immunolabeling, we found that COX-1 was coexpressed with AT 1 R in SFO neurons. Consistent with this finding, ANG II-triggered PGE 2 release from SFO cells was AT 1 R and COX-1 dependent. In addition, ANG II induced ROS formation and L-type voltagegated Ca 2ϩ currents (L-VDCCs) via PLA 2 , COX-1-derived PGE 2 , and EP 1 R. Finally, Nox2 was identified as the source of ANG II-induced, EP 1 R-mediated ROS production in the SFO. 2] were purchased from Bio-Synthesis (Lewisville, TX). Dihydroethidium (DHE) and calcein AM were purchased from Invitrogen (Carlsbad, CA). The COX-1 antibody (M-20, No. sc-1754, an affinity-purified goat antibody raised against the COOHterminus of mouse COX-1) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA), and the GFP antibody (GFP-1020, a chicken antibody) was purchased from Aves Laboratories (Tigard, OR).
MATERIALS AND METHODS

Materials
Electron microscopy. Tissue was processed and analyzed as previously described (19, 43) . In brief, three males of AT 1R-eGFP and WT age-matched mice were anesthetized with pentobarbital sodium, and their brains were fixed by perfusion with heparin-saline (1,000 U/ml), followed consecutively by 3.8% acrolein (Polysciences) in 2% paraformaldehyde in 0.1 mol/l phosphate buffer and then 2% paraformaldehyde in phosphate buffer. Coronal 40-m vibratome sections were cut through the SFO and transferred to a storage solution for storage at Ϫ25°C. Random SFO sections were incubated for 48 h (24 h at room temperature, and 24 h at 4°C) in 0.1 mol/l Tris-buffered saline-0.1% bovine serum albumin solution containing either 1) a cocktail of the COX-1 antibody [1:150, for immunogold (ImG) labeling] and the GFP antibody [1:2,500, for immunoperoxidase (ImP) labeling] for double labeling or 2) the COX-1 antibody (1: 2,000, for ImP labeling) for single labeling. Sections were then placed for 30 min in either biotinylated secondary donkey anti-chicken or anti-goat IgG (1:400, Jackson), and avidin-biotin peroxidase complex (ABC Elite Kit, Vector). Bound peroxidase was visualized with 3,3=-diaminobenzidine (Sigma-Aldrich) and hydrogen peroxide (H 2O2). Tissue processed for dual immunolabeling was additionally incubated overnight in a 1-nm gold particle-conjugated donkey anti-goat secondary IgG (1:50, EMS), followed by postfixation in 2% glutaraldehyde (10 min) and silver intensification using an IntenSE-M Kit (7 min, Amersham). Sections were then postfixed in 2% osmium tetroxide and embedded in EM bed-812 (EMS). Ultrathin sections (70 nm) containing the SFO were cut and collected onto thin bar copper mesh grids (EMS), and counter stained with uranyl acetate and Renyold's lead citrate before examination on a Philips CM10 Technai electron microscope (FEI Company). To quantify COX-1 ImG labeling, undamaged regions of neuropil adjacent to the plastic/tissue interface (i.e., near to the tissue surface) in randomly selected grid square fields, in central portions of the SFO, were examined. In two grids from each AT 1R-eGFP animal, all ImG particles in such fields were categorized in terms of 1) the type of ultrastructural process they were associated with, in neurons (i.e., soma, dendrite, terminal, and axon), glia, and vascular glia (associated with fenestrated capillaries or vascular epithelial cells) and 2) whether that process also contained AT 1R-eGFP ImP labeling.
Enzymatic dissociation of cells from the SFO and the PVN tissues. The brain was quickly removed and transferred to a chamber containing ice-cold sucrose-artificial cerebrospinal fluid composed of (in mmol/l) 26 NaHCO 3, 1 NaH2PO4, 3 KCl, 5 MgSO4, 0.5 CaCl2, 10 glucose, and 248 sucrose, oxygenated with 95% O 2-5% CO2 (pH 7.4). Coronal section of 300 m in thickness were obtained using Leica VT1000s vibratome (Leica Microsystems) and stored in a customdesigned chamber containing lactic acid-artificial cerebrospinal fluid (l-aCSF) composed of (in mmol/l): 124, NaCl; 26, NaHCO 3; 5, KCl; 1, NaH 2PO4; 2, MgSO4; 2, CaCl2; 10, glucose; 4.5, lactic acid; oxygenated with 95% O 2 and 5% CO2, pH 7.4. The location of the SFO is characterized by its dorsal connection with the hippocampal commissure, protruding into the third ventricle of the brain. The brain section containing the SFO was put under a dissection light microscope. The SFO tissue (ϳ450 m in diameter) was quickly punched out and placed in oxygenated l-aCSF containing 0.01% thermolysin and 0.01% pronase for enzymatic digestion for 2 h at 33°C. The PVN region was identified using lateral ventricle, fornix, and optic tracts as landmarks. The PVN was punched out under dissection microscope and placed in oxygenated l-aCSF containing 0.01% thermolysin and 0.01% pronase for enzymatic digestion for 2 h at 33°C, followed by washing with l-aCSF and trituration of the digested tissue with only 0.3 ml l-aCSF to obtain cell suspension. The cell suspension was quickly plated on a 35-mm petri dish coated with poly-L-lysin for 5-8 min before starting perfusion with oxygenated l-aCSF. Calcein AM (1 mol/l), a nonfluorescent and cell permeant compound that is hydrolyzed by intracellular esterases into the fluorescent anion calcein, was used to test the viability of isolated SFO cells (44) following enzymatic dissociation.
PGE2 assay. WT, COX-1 Ϫ/Ϫ , or COX-2 Ϫ/Ϫ mice were euthanized, and the SFO and PVN tissues were collected from mice (2 SFO tissues per biological sample). The dissociated SFO cells were obtained by enzymatic digestion, as described above. Each sample was pretreated with vehicle or ANG II (100 nmol/l) and various chemical modulators for 30 min before its supernatant was extracted for detection of PGE2 concentration using an EIA kit (Cayman Chemical).
ROS detection. Intracellular ROS levels in dissociated SFO cells were assessed using DHE. SFO cells were dissociated as described above, moved to a petri dish mounted on Nikon diaphot 300 inverted microscope (Nikon, Japan), and incubated with DHE (2 mol/l) for 30 min. The fluorescence intensity was measured before (vehicle) and after application of ANG II or PGE2 using an ethidium bromide (DNA complex) filter (Chroma Technology, Bellows Falls, VT) with the spectrum of an excitation maximum 510 nm and an emission maximum 605 nm, which indicates the presence of superoxide (O 2 Ϫ ) and possibly other ROS such as H2O2, hydroxyl radical, and peroxynitrite (47) . To validate ROS measurement using this system, we tested the capability of exogenous H2O2 to increase DHE signal in the SFO cells. The increase in DHE-derived fluorescence observed after treatment of SFO cells with H2O2 is attributed to intracellular stimulation of superoxide production by H2O2 (65) . Addition of H2O2 (30 and 300 mol/l) to the dissociated SFO cells did increase DHE signal in a dose-dependent manner (data not shown here). Data are expressed as DHE fluorescence intensity relative to control samples (Ft/Fo).
Whole cell-patch recording. The dissociated SFO cells were placed in a 35-mm petri dish mounted on the Nikon inverted microscope and perfused with the oxygenated l-aCSF at room temperature (24 -26°C). The whole cell-patch recording of isolated SFO neurons was performed using an Axopatch-200A patch-clamp amplifier (Molecular Devices) and a glass electrode pulled by a P-97 micropipette puller (Sutter Instruments) with tip resistance of 3-5 M⍀ when filled with a pipette solution containing (in mmol/l) 145 Cs-gluconate, 17 CsCl, 5 EGTA, 1 MgCl2, 10 HEPES, 2 ATP, and 0.2 cAMP (pH 7.3). Series resistance and membrane capacitance were compensated. Bipolar SFO neurons were visualized following dissociation. TTX-sensitive voltage-gated Na ϩ currents were recorded to confirm that the patched cell was a neuron. Two millimole/liter Ca 2ϩ in l-aCSF was used as a charge carrier for the voltage-gated Ca 2ϩ currents elicited by a 500-ms depolarization pulse from a holding potential at Ϫ60 mV to stepping potentials between Ϫ50 and ϩ20 mV. To selectively record the long-lasting (L)-type Ca 2ϩ current, the selective voltage-gated Na ϩ channel blocker TTX (1 mol/l) and N-type Ca 2ϩ channel blocker Ctx-GVIA (1 mol/l) were added to the perfusion buffer in some patched SFO neurons. The amplitude of L-VDCC was measured at the end of 500-ms pulse (57, 58) . The amplitudes of Ca 2ϩ currents were analyzed using pClamp 8 (Molecular Devices, Sunnyvale, CA).
Data analysis. Data are expressed as means Ϯ SE. Multiple comparisons were evaluated by ANOVA, followed by post hoc analysis using Tukey's test with paired comparison. Differences were considered statistically significant at P Ͻ 0.05.
RESULTS
COX-1 is coexpressed with AT 1 R in SFO neurons.
The SFO contains a network of diversified neurons, neuronal processes, and glial cells. To establish a structural framework from which to best unravel key functional interactions, we performed ultrastructural labeling of COX-1 and AT 1 R within the SFO. Examination of central portions of the SFO revealed that COX-1 ImG labeling was common and was concentrated in postsynaptic neuronal processes and glial processes (Fig. 1) . Quantification of this distribution pattern (Fig. 1D ) demonstrated that 60% of the ImG particles were associated with either neuronal somata or dendrites, and 30% were associated with glial processes in the neuropil (total number of ImG particles examined, 1,072). In addition, 68% of the COX-1 ImG-labeled postsynaptic neuronal processes (i.e., somal and dendritic) also displayed AT 1 R-eGFP ImP labeling. The results confirm that AT 1 R and COX-1 are spatially linked and provide anatomical support for the theory that COX-1 may be associated with ANG II-elicited generation of PGE 2 in SFO neurons.
ANG II-triggered endogenous PGE 2 release from dissociated SFO cells is dependent on AT 1 R, PLA 2 , and COX-1. Following dissociation of SFO cells, calcein AM (1 mol/l) was loaded to isolated cells to check viability. As shown in Fig isolated SFO cells, including neurons, remained viable following 50 min of calcein labeling (86.7 Ϯ 4.7%, P Ͼ 0.05 vs. 0 min, cell number from each experiment ϭ 48 -54, number of experiments ϭ 3) (Fig. 2B) . Taken together, this proved the viability of the isolated SFO cells and neurons and allowed us to perform further functional studies in vitro.
Considering that COX-1 was present in SFO neurons, often in the same cells as AT 1 R, we sought to determine whether ANG II would elicit PGE 2 production from dissociated SFO cells and, if so, what pathway might be involved in the PGE 2 release (6, 29, 54). As shown in Fig. 2C , the basal amount of endogenous PGE 2 released from WT SFO cells following incubation in vehicle for 30 min was 1.69 Ϯ 0.2 ng/mg (N ϭ 9). Incubation in ANG II (100 nmol/l) for 30 min elicited a significant increase in endogenous PGE 2 release from WT SFO cells (ϩ208 Ϯ 38.5%, P Ͻ 0.01 vs. WT SFO vehicle, N ϭ 5). This effect was blunted when the cells were preincubated with the AT 1 R antagonist losartan (3 mol/l, 58.8 Ϯ 23.5%, P Ͼ 0.05 vs. WT SFO vehicle, N ϭ 9) or the PLA 2 antagonist ACA (1 mol/l, 88.2 Ϯ 29.4%, P Ͼ 0.05 vs. WT SFO vehicle, N ϭ 8). Furthermore, incubation of COX-1 Ϫ/Ϫ SFO cells in ANG II did not increase PGE 2 release (Ϫ64.5 Ϯ 8.3%, P Ͼ 0.05 vs. WT SFO vehicle, N ϭ 6). Incubation of COX-2 Ϫ/Ϫ SFO cells in ANG II partially but significantly inhibited PGE 2 release (ϩ89.4 Ϯ 12.4%, P Ͻ 0.05 vs. WT SFO vehicle, N ϭ 5). As shown in Fig. 2D , the basal levels of endogenous PGE 2 released from WT PVN cells following incubation in vehicle and ANG II (100 nmol/l) were relatively low compared with WT SFO cells (vehicle, 0.75 Ϯ 0.49 ng/mg N ϭ 4; and ANG II, 0.57 Ϯ 0.47 ng/mg; P Ͼ 0.05, N ϭ 4). These results indicate that ANG II elicits endogenous PGE 2 release from SFO cells, and this PGE 2 production may be dependent on the conversion of AA by COX-1. Importantly, this provides mechanistic support for our previous finding that COX-1-dependent PGE 2 formation plays a key role in ANG II-induced hypertension in the SFO.
ANG II and PGE 2 induce increased ROS production in SFO cells.
It has been established that the SFO mediates systemic ANG II-dependent hypertension via increased production of ROS (6, 66, 68) . Moreover, we have recently reported that a single dose (100 nmol/l) of ANG II causes a significant increase in ROS formation in WT SFO cells in vitro, a response that was absent in either EP 1 R Ϫ/Ϫ or COX-1 Ϫ/Ϫ SFO cells, but was intact in COX-2 Ϫ/Ϫ SFO cells (6) . Using the EP 1 R antagonist SC51089, we also confirmed that ANG IIinduced ROS formation in WT SFO cells was via EP 1 R. In addition, PGE 2 (100 nmol/l) elicited increases in ROS formation to a similar extent as ANG II (6) . These data indicate that PGE 2, via EP 1 R, serves as a downstream signal in ANG IIinduced ROS formation. Using DHE as a fluorescence ROS indicator, we thus focused on the roles of other critical elements in ANG-II signaling pathway, including AT 1 R, PLA 2 , and NADPH oxidase, in ANG II-and PGE 2 -induced ROS formation in SFO cells.
As shown in Fig. 3 , both exogenous ANG II (N ϭ 8 -24 per individual dose) and PGE 2 (N ϭ 6 -18 per individual dose) increased the DHE signal in a dose-dependent manner in dissociated WT SFO cells. Coapplication of the AT 1 R antagonist losartan (3 mol/l) significantly inhibited the increase in DHE induced by ANG II, but not by PGE 2 (Fig. 3, B and C) .
As shown in Fig. 4 , ANG II (100 nmol/l) induced an increase in DHE signal (ϩ25 Ϯ 3%, P Ͻ 0.01 vs. vehicle, n ϭ 9), a response that was blocked by the general PLA 2 inhibitor ACA (1 mol/l), the COX-1 inhibitor SC560 (10 mol/l), the NADPH oxidase peptide inhibitor gp91-ds (1 mol/l) and in Nox2 Ϫ/Ϫ cells (Fig. 4A) , but not by s-gp91-ds. PGE 2 (100 nmol/l) also induced a similar increase in ROS formation (ϩ32 Ϯ 8.2%, P Ͻ 0.01 vs. vehicle, n ϭ 7) that was blocked by gp91-ds (1 mol/l) and in Nox2 Ϫ/Ϫ cells. This effect, however, was not blocked by ACA (1 mol/l), SC560 (10 mol/l), or s-gp91-ds (Fig. 4B) . Taken together, these results indicate that PLA 2 -mediated PGE 2 production is downstream of AT 1 R but upstream of COX-1 and that Nox2 is the source of ANG II and PGE 2 -induced ROS formation in SFO cells.
ANG II potentiates the L-VDCC in SFO neurons via AT 1 R. In addition to generation of ROS, the AT 1 R is also involved in voltage-dependent Ca 2ϩ influx in the central nervous system (58, 70) . Since the L-VDCC is a key signal for the regulation of short-and long-term potentiation and neurotransmitter release (12, 16, 46, 60, 64) , we next sought to determine whether the AT 1 R-mediated signals were linked with the L-VDCC in SFO neurons. The VDCC in the mouse SFO neurons are composed of transient fast-inactivating and slowly inactivating components (59) . Representative traces show that following application of TTX (1 mol/l) to block voltage-gated Na ϩ currents and Ctx-GVIA (1 mol/l) to inhibit the transient, fast inactivating N-type Ca 2ϩ currents in SFO neurons, the LVDCCs were well distinguished (Fig. 5A) . Biophysically, the current-voltage curves of this L-VDCC show that it was maximally elicited by a depolarization pulse from the holding potential at Ϫ60 mV to the stepping potential at Ϫ10 mV (Fig.  5B) . Pharmacologically, it was activated by ANG II (100 nmol/l), which is in agreement with previous observation in the SFO (61) and other central neurons (Wang et al. 2004 ). Such effect was attenuated by coapplied losartan (3 mol/l) (Fig. 5,  A and C) . However, further coapplication of the L-type Ca 2ϩ channel activator BAY K 8644 (2 mol/l, P Ͻ 0.01 vs. vehicle, N ϭ 16) restored increased currents, but the L-VDCC was completely inhibited by the L-type Ca 2ϩ channel blocker nifedipine (2 mol/l, P Ͻ 0.01 vs. vehicle, N ϭ 6) (Fig. 5 , A and C) and nonselective Ca 2ϩ channel blocker Cd 2ϩ (100 mol/l, P Ͻ 0.01 vs. vehicle, N ϭ 6) (12, 58) (Fig. 5C ). Taken together, ANG II (100 nmol/l) triggered a potentiation of the L-VDCC in SFO neurons (ϩ53.3 Ϯ 5.8%, P Ͻ 0.01 vs. vehicle, N ϭ 9), a response that was blocked by the AT 1 R antagonist losartan (3 mol/l; Ϫ15.7 Ϯ 7.3%, P Ͻ 0.05 vs. vehicle, N ϭ 9) (Fig. 5C) . These results indicate that ANG II-elicited potentiation of the dihydropyridine-sensitive L-VDCC in SFO neurons is mediated by AT 1 R.
PLA 2 , COX-1, and EP 1 R are involved in ANG II-induced L-VDCC in SFO neurons.
Since the EP 1 R is also involved in presynaptic Ca 2ϩ influx (24) and glutamate release in the central nervous system (4), we used pharmacological and electrophysiological approaches to determine whether the PLA 2 /COX-1/EP 1 R signaling molecules that link to ANG II-induced ROS generation also play a role in the ANG II-mediated potentiation of L-VDCC in SFO neurons. As shown in L-type Ca 2ϩ currents was abolished in EP 1 R Ϫ/Ϫ SFO neurons (P Ͼ 0.05 vs. vehicle, N ϭ 7) (Fig. 6B) . Figure 6C shows the time course of ANG II-induced enhancement in the amplitude of L-VDCC currents in one single isolated SFO neuron. The ANG II-enhanced L-VDCC was reversed by the coapplied EP 1 R antagonist SC51089 (10 mol/l) (Fig. 6C) . These results establish that PLA 2 , COX-1, and EP 1 R act downstream of ANG II for potentiation of L-VDCC in SFO neurons.
Nox2-derived ROS contribute to ANG II-induced L-VDCC in SFO neurons.
We next we sought to determine the molecular factor responsible for L-VDCC activation and its subcellular localization. Since ROS are known modulators of L-VDCC and they are downstream of the ANG-II signaling pathway, we were curious as to whether Nox2-derived ROS are involved in ANG II-induced L-type Ca 2ϩ influx. We examined the effects of the ROS scavenger MnTBAP and Nox2 Ϫ/Ϫ SFO neurons on ANG II-elicited L-VDCC. As shown in Fig. 7A , ANG IIinduced potentiation in L-VDCC in WT SFO neurons (P Ͻ 0.01 vs. vehicle, N ϭ 6) was abolished by pretreatment with MnTBAP (100 mol/l, P Ͼ 0.05 vs. vehicle, N ϭ 6). This response was also abolished in Nox2 Ϫ/Ϫ SFO neurons (P Ͼ 0.05 vs. vehicle, N ϭ 4), implying that Nox2-derived ROS are PGE 2 potentiates L-VDCC via EP 1 R and Nox2 in SFO neurons. PGE 2 is known to induce an increase in Ca 2ϩ influx in the central nervous system (4, 32) . Therefore, we further analyzed whether PGE 2 , as a downstream signal of ANG-II pathway, is capable of inducing L-VDCC in SFO neurons and, if so, whether it involves the activation of EP 1 R/Nox2 pathway. We examined the effect of applying antagonists for AT 1 R, PLA 2 , and EP 1 R or deleting EP 1 R and Nox2 on PGE 2 -induced L-VDCC in SFO neurons. As shown in Fig. 7B , PGE 2 (100 nmol/l) induced potentiation of L-VDCC in SFO neurons (55.6 Ϯ 9.9%, P Ͻ 0.01 vs. vehicle, N ϭ 16), a response that was unaffected by losartan (3 mol/l, P Ͻ 0.01 vs. vehicle, N ϭ 4) or ACA (1 mol/l, P Ͻ 0.01 vs. vehicle, N ϭ 5). However, coapplied SC51089 (10 mol/l, SC, N ϭ 7) or genetic deletion of EP 1 R (N ϭ 5) inhibited L-VDCC enhancement induced by PGE 2 (P Ͼ 0.05 vs. vehicle) (Fig. 7B) . Moreover, coapplied MnTBAP (100 mol/l) or genetic deletion of Nox2 (N ϭ 5) also abolished the L-VDCC potentiated by PGE 2 (P Ͼ 0.05 vs. vehicle) (Fig. 7B) . These results indicate that the EP 1 R and Nox2 serve as critical signals linking PGE 2 to L-type Ca 2ϩ channels in the SFO. 2 . Our ultrastructural data show that COX-1 labeling is concentrated in postsynaptic neuronal processes in the SFO. Assuming that endogenous PGE 2 derived by postsynaptic COX-1 activates presynaptic EP 1 R (24), which may be responsible for ANG II-induced potentiation of L-VDCC in isolated SFO neurons, we next sought to investigate whether locally generated PGE 2 derived from COX-1 in neighboring cells potentiates L-VDCC in the patched neuron. Adding SC560 (200 nmol/l) to the pipette buffer to inhibit intracellular COX-1 in the SFO neuron patched via the whole cell configuration (Fig. 8A) , we found that exogenously applied ANG II (100 nmol/l) still increased L-VDCC (P Ͻ 0.01 vs. vehicle, n ϭ 9). However, this response was blocked by extracellular coapplication of SC51089 (10 mol/l, P Ͼ 0.05 vs. vehicle, n ϭ 6) (Fig. 8B) . Further coapplication of BAY K 8644 (2 mol/l) reversed the inhibition of L-VDCC potentiation (P Ͻ 0.01 vs. vehicle, n ϭ 4) in the same patched neuron, indicating that the L-type Ca 2ϩ channels retained their functionality (Fig.  8B) . These results indicate that endogenous PGE 2 derived from ANG II-activated COX-1 in neighboring SFO cells could exert paracrine action by potentiating L-VDCC through EP 1 R. This assumption is further supported by our ultrastructural labeling studies that indicate extensive expression of COX-1 in SFO neuronal somata, dendrites, and glial cells.
Paracrine regulation of L-VDCC in SFO neurons by endogenous PGE
DISCUSSION
COX-derived prostanoids and other endogenous fatty acid metabolites are involved in a wide variety of biological processes (1, 8, 27, 45, 50) and have been implicated in blood pressure regulation (20, 45) . The SFO (11, 14) , PGE 2 /EP 1 R signaling (6, 7, 21) , ROS (6, 66, 68) , and voltage-gated Ca SFO. We also demonstrate that COX-1 is highly concentrated in neuronal postsynaptic processes in the central SFO, particularly in the processes of cells that coexpress the AT 1 R and that COX-1 is the major source for the ANG II-activated PGE 2 release in the SFO. Furthermore, ANG II-evoked PGE 2 and ROS formation in dissociated SFO cells is prevented by deletion of COX-1 and partially attenuated by deletion of COX-2. ANG II or PGE 2 -potentiated ROS and Ca 2ϩ currents are dependent on PLA 2 , EP 1 R, and ROS. These results support the notion that COX-1-derived PGE 2 and EP 1 R signaling in the SFO are critical for slow-pressor ANG-II hypertension (6) and provide a detailed signaling pathway linking ANG II with ROS and L-VDCC, as summarized schematically in Fig. 9 . As previously reported (53, 66) , we speculate that this ANG II-induced intracellular increase in O 2 Ϫ may also lead to an increase in extracellular H 2 O 2 . Additionally, the present in vitro data also support the in vivo results recently published by our group (6) .
Ultrastructural labeling of SFO neurons supports paracrine action of PGE 2 . The neuronal location of AT 1 R in the SFO was illustrated by GFP labeling in postsynaptic somata and dendrites, many of which also contained COX-1. The colocalization of AT 1 R and COX-1 in the SFO provides valuable ultrastructural support for the functional interaction seen between ANG II and COX-1 in dissociated SFO cells. In duallabeled somatodendritic profiles, COX-1 ImG labeling was present in the cytoplasmic compartment of SFO neurons. Plasmalemmal labeling of COX-1 was also seen in small-and medium-sized dendrites receiving synaptic input from one or more axon terminals. Postsynaptic coexpression of COX-1 and AT 1 R in SFO neurons indicates that COX-1 is likely to be associated with AT 1 R-elicited generation of PGE 2 and that release of PGE 2 from postsynaptic sites may modulate EP 1 receptors at presynaptic sites (24) . In addition to COX-1, our recent EM data indicate that COX-2 is also present in SFO neurons that express AT 1 R (unpublished data).
It is notable that PGE 2 is also produced and released from glial cells (29 (2, 37 ) that provides a novel mechanism for the regulation of Ca 2ϩ influx and excitability. Using a TIRF imaging-based approach, a pathway has been characterized that functionally links subplasmalemmal generation of endogenous ROS that precede and colocalize with enhanced L-type Ca 2ϩ channel activity via activation of PKC␣ in cerebral arterial smooth muscle (2) . Further studies are needed to determine how ROS are functionally linked to L-VDCC potentiation in the SFO.
Potential contribution of L-type Ca 2ϩ currents to SFO function. Though the mechanisms underlying ANG II-induced sympathoexcitation via SFO neuronal projections to other autonomic nuclei remain elusive, it is likely that voltage-gated L-type Ca 2ϩ influx is involved in presynaptic glutamate release and therefore synaptic plasticity, such as LTP (16, 46, 64) . For LTP mediated by increased release of glutamate in the corticolateral nucleus of the amygdala, L-VDCCs are necessary for the persistent expression, and possibly the induction, of presynaptic cortico-LA LTP. Whereas L-VDCCs only weakly contribute to baseline release, they contribute significantly to increased synaptic transmission (16) . On the other hand, the electrical stimulation-induced LTP of synapses onto the excitatory narrow-field vertical neurons of the sSC requires postsynaptic Ca 2ϩ elevation by both NMDARs and L-type Ca 2ϩ channels during induction but not maintenance (64) . Therefore, L-type Ca 2ϩ channels might be required for both induction and persistent expression of presynaptic LTP.
The role of SFO L-type voltage-dependent Ca 2ϩ channels in ANG II-induced hypertension. The functional link between ANG II and voltage-gated Ca 2ϩ influx in central neurons, including sympathetic neurons, has been previously reported (15, 33, 61, 70) . In vivo, it is evident that the SFO sends the ANG-II peptidergic efferent to the PVN neurons (13, 30, 31) and that the ANG II-induced hypertension mediated via the SFO is attenuated by intracerebroventricular administration of the L-VDCC blocker nifedipine (48) . In vitro, L-VDCC plays an important role in the regulation of peptidergic neurotransmitter release from presynaptic axonal terminals of central neurons (59) . Therefore, it can be speculated that AT 1 R in SFO sensory neurons are activated by circulating ANG II, which increases Ca 2ϩ influx mediated by L-VDCC through EP 1 R and ROS pathways. Since increments in intracellular calcium concentration lead to ANG-II release from axonal terminals in the PVN-projecting SFO neurons (18) , L-VDCC potentiation may cause excitation of presympathetic neurons in the PVN, leading to hypertension.
Perspective and significance. The in vitro results described here, along with our recently published in vivo results (6) , provide strong evidence that EP 1 R-mediated ROS formation via Nox2-NADPH oxidase in the SFO may provide useful targets for the treatment of hypertension. SFO-targeted treatment with cytoplasmic superoxide dismutase has proven to be as effective in ameliorating ANG-II hypertension as chronic intracerebroventricular infusion of the AT 1 R antagonist losartan (68) . Peripheral administration of the AT 1 R antagonist losartan may also target the AT 1 R expressed in the SFO because of its lack of a normal blood-brain barrier (9) . In addition, blocking the ANG-II/PGE2/L-VDCC pathway in the SFO might be beneficial for the treatment of hypertension (51) .
In conclusion, the present study used diverse cutting-edge technologies, including electron microscopy, EIA, ROS imaging, patch recording, and null mutant mice to comprehensively determine that ANG II-mediated PLA 2 and PGE 2 signals are coupled with ROS formation and intracellular Ca 2ϩ homeostasis in SFO neurons. Additionally, as PGE 2 is also released from glial cells, future studies should focus on the identification of possible distinct contributions by different cell types to ANG II-triggered PGE 2 release. Taken together, our findings are a critical step toward a more complete understanding of ANG-II signaling in the SFO and may provide novel targets for future antihypertensive therapy.
